Omnitura Therapeutics Inc.
Omnitura Therapeutics is a privately held biopharmaceutical company engaged in the commercialization of innovative technologies for fundamentally complex and heterogeneous nature of cancer. Its leading product, Aneustat(OMN54) which is developed for the treatment of lung and prostate cancer entered into clinical stage of development. Additionally, it is used as an adjuvant to surgery, radiation therapy, chemotherapy, and for maintenance for many tumor types. The company developed a novel therapy Multifunctional Multitargeted (MFMT) which addresses the fundamentally heterogeneous nature of cancer. The company is headquartered in Henderson, the US.